CAS SciFinder Discovery Platform
Product Description
CAS
-
Country/Region:United States
-
Founded:1907
-
On CPHI since:2026
-
Employees:1000 - 4999
Company types
Primary activities
Categories
Specifications
CAS
-
Country/Region:United States
-
Founded:1907
-
On CPHI since:2026
-
Employees:1000 - 4999
Company types
Primary activities
More Products from CAS (4)
-
Product CAS BioFinder®
CAS, the world leader in scientific information, standardizes the biology and chemistry data needed for drug discovery, and draws deep connections between pathways, biomarkers, antibodies, small molecules, assays, and more. CAS BioFinder combines the world’s most trusted, human-curated scientific data with... -
Product CAS Connections
CAS Connections brings the CAS Content Collection™ and CAS Newton℠ agentic AI directly into your existing research platforms, AI environments, and agentic workflows — so the science your organization depends on is available wherever decisions are made. -
Product CAS Custom ServicesSM
Innovation opportunities stay hidden when scientific data is fragmented, unstructured, or hard to trust. CAS Custom Services℠ offers expert scientific data and knowledge management consulting, tailored to your business needs. By partnering directly with science and technology experts at CAS, you can access... -
Product CAS Registry Services
CAS Registry Services helps you obtain CAS Registry Numbers® (CAS RNs®), CA Index Names, and substance information for reports, proprietary files, online searching, and regulatory applications.
CAS resources (4)
-
Whitepaper Does your drug discovery budget fund novel ideas or data crunching?
This white paper examines how fragmented data tools and inconsistent scientific information consume researcher time in drug discovery, and how a centralized, curated data platform can recover that capacity and improve R&D efficiency. -
Whitepaper How unified biological and chemical data strengthens early drug discovery decisions
Discover how integrating biological and chemical data accelerates early-stage drug discovery, improves cross-functional alignment, and reduces late-stage failure risks.
This white paper explores how unified biological and chemical data can transform early discovery workflows to align teams, uncover hidden opportunities, and reduce late-stage failure risk. Learn how integrating biological and chemical insights strengthens early-stage decisions and improves ROI. -
Whitepaper How data limitations hold back AI in pharma R&D
This white paper gives readers a clear view of the data conditions needed for AI to deliver reliable results in pharma. It shows how fixing the data foundation improves model accuracy, cuts out rework, and removes the friction that keeps AI from scaling. -
Whitepaper Turn untapped pharma data into R&D fuel: Three actionable steps to unlock AI predictive power
AI in pharma R&D is only as strong as the data behind it. This white paper outlines tips and success factors for eliminating blind spots and boosting predictive power with a smarter data strategy.